More than one-third of advanced melanoma patients treated in a study of Bristol-Myers Squibb’s Opdivo have survived at least five years, researchers said, providing fresh evidence of the durable benefit cancer immunotherapy agents have for some patients.
from WSJ.com: US Business http://ift.tt/1STVWtn
via IFTTT
No comments:
Post a Comment